TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8204703
Drug: UDCA 10
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 10 mg/kg/day for one year
Study: 3301452
Drug: Long-acting propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol, 160 mg once daily
Study: 3301452
Drug: Conventional propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol, 40 mg three times daily
Study: 29941495
Drug: Cholecalciferol (D3)
Normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (D3) 4,000 IU daily
Study: 26678311
Drug: Low-dose bexarotene
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bexarotene plus PUVA
Study: 23989505
Drug: Dental care
Normalized name: Arm And Hammer Dental Care Mint Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental care program (complimentary care before and during oncological therapy)
Study: 4025156
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion of amrinone (200 micrograms/kg/hr for 30 minutes, 400 micrograms/kg/hr for 30 minutes and then 800 micrograms/kg/hr for 30 minutes)
Study: 4025156
Drug: High-dose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusion of amrinone (800, 1,600 and 3,200 micrograms/kg/hr sequentially, each for 30 minutes)
Study: 24906836
Drug: Ayurvedic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) during chemotherapy (Arm 1)
Study: 24906836
Drug: Ayurvedic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic drugs (Mauktikyukta Kamdudha and Mauktikyukta Praval Panchamruta) after chemotherapy (Arm 2)
Study: 24906836
Drug: Suvarnabhasmadi formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvarnabhasmadi formulation in addition to MKD and MPP after chemotherapy (Arm 3)
Study: 20334478
Drug: Erdosteine (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (triple therapy consisting of pantoprazole, amoxicillin, and clarithromycin plus erdosteine)
Study: 20334478
Drug: Placebo (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (triple therapy plus placebo)
Study: 18361800
Drug: Aprotinin (500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (500,000 IU after induction and repeat dose after chest closure)
Study: 16418548
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology (60 minutes, twice a week for five weeks)
Study: 10417464
Drug: suxamethonium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 0.1 mg.kg‐1 intravenously
Study: 7473009
Drug: ePTFE membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePTFE membrane alone (G)
Study: 7473009
Drug: ePTFE membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePTFE membrane plus root conditioning (G + D)
Study: 7473009
Drug: ePTFE membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePTFE membrane plus root conditioning plus composite graft (G + D + B)
Study: 27484436
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with vitamin K2 (45 mg/day) and risedronate (2.5 mg/day or 17.5 mg/week)
Study: 27484436
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg/day or 17.5 mg/week) alone
Study: 27484436
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with vitamin K2 and risedronate
Study: 22534814
Drug: Pralatrexate 190
Normalized name: Pralatrexate
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pralatrexate 190 mg/m on days 1 and 15 of a 28-day cycle
Study: 17293707
Drug: Quetiapine addition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine addition to serotonin reuptake inhibitors
Study: 11453610
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta agonists, theophylline, cromolyn, inhaled corticosteroids
Study: 10938493
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 ml of 1.4-4.6% NaCl) b.i.d.
Study: 10938493
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide (500-1000 mg) as a bolus b.i.d. without HSS.
Study: 8794422
Drug: Matrix transdermal
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix transdermal estradiol delivery system worn for 7 consecutive days
Study: 8794422
Drug: Reservoir transdermal
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reservoir transdermal patch worn for 4 days followed by another patch for 3 days
Study: 1536785
Drug: 5% 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-aminosalicylic acid (5-ASA) cream applied three times daily for up to 14 days
Study: 1536785
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied three times daily for up to 14 days
Study: 6391735
Drug: Oral mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mixed grass‐pollen vaccine
Study: 30895694
Drug: Purslane seeds
Normalized name: Purslane
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purslane seeds (10 g/day) with low-calorie diet
Study: 22672949
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical therapy
Study: 18468831
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg single dose, intramuscular)
Study: 12020525
Drug: Azithromycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1.5 g total dose over 5 days)
Study: 12020525
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1.5 g total dose over 5 days)
Study: 8949472
Drug: Written test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written test administered 1 month before and directly after the training
Study: 26586096
Drug: F1.8 formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: F1.8 formula (1.8 g protein/418.4 kJ)
Study: 26586096
Drug: F2.7 formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: F2.7 formula (2.7 g protein/418.4 kJ)
Study: 24613908
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for at least 5 months
Study: 12030948
Drug: Red pepper
Normalized name: Red pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red pepper powder (2.5 g/day for 5 weeks)
Study: 7294869
Drug: Topical paraffin
Normalized name: Paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paraffin
Study: 26091023
Drug: 3% Hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Hypertonic Saline (250 mL)
Study: 26091023
Drug: 7.5% Hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% Hypertonic Saline (250 mL)
Study: 26091023
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's Solution (LRS) (250 mL)
Study: 15978753
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen 0.625 mg/day (CEE 0.625 mg)
Study: 15978753
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estradiol 50 microg/day (tE2)
Study: 15978753
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day (CEE 0.625 mg/MPA 2.5 mg)
Study: 15978753
Drug: Oral 2
Normalized name: SYRINGE,ORAL 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 2 mg 17‐beta estradiol combined with 1 mg norethistrone acetate (E2/norethistrone)
Study: 1893805
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplementation (zinc sulfate 600 mg/day)
Study: 29140378
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed prosthesis (group 1)
Study: 29140378
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed prosthesis (group 2)
Study: 18156641
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of elemental iron/daily added to school meals (group A)
Study: 18156641
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of elemental iron/daily added to school meals (group B)
Study: 11682399
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IM
Study: 7929824
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 21.5 pmol/kg per min for 2.5 h during hyperinsulinemic-euglycemic clamp
Study: 7929824
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline infusion (0.45% saline)
Study: 29453433
Drug: Earlier Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier Oral Feeding Group (initiated at 30 weeks' PMA)
Study: 29453433
Drug: Later Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later Oral Feeding Group (initiated at 33 weeks' PMA)
Study: 27317358
Drug: Featback supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Featback supplemented with low-intensity (weekly) digital therapist support
Study: 24289887
Drug: rhEPO (40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (40,000 IU intravenously, twice a week for 5 weeks)
Study: 16614713
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with activities from 1000 to 6000 MBq
Study: 16614713
Drug: First course
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First course of radioiodine therapy
Study: 10856472
Drug: Pulsatile IV
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile IV GnRH (10-20 microgram/90 min) after GnRH‐agonist down‐regulation
Study: 10856472
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (50-150 mg; cycle days 3-7)
Study: 9173664
Drug: Mannitol and
Normalized name: Mannitol and sorbitol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol and low sodium solution
Study: 9173664
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol and high sodium concentration solution
Study: 9173664
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol and low sodium solution
Study: 3031260
Drug: High phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High phosphorus intake (1.67 mmol/kg/d, 50 mg/kg/d)
Study: 3031260
Drug: Moderate phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate phosphorus intake (1.34 mmol/kg/d, 40 mg/kg/d)
Study: 3031260
Drug: Low phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phosphorus intake (1.01 mmol/kg/d, 30 mg/kg/d)
Study: 24739318
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisone daily for 5 days
Study: 9539190
Drug: Indole‐3-carbinol (13C),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indole‐3-carbinol (13C), 400 mg for two months
Study: 7961534
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy (exposure in vivo and response prevention)
Study: 7961534
Drug: Naturalistic behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic behavior therapy
Study: 31821098
Drug: Oxybutynin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin (0.2 mg/kg 3 times daily)
Study: 31165710
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment group (ITG) - Big White Wall (BWW) intervention for 3 months
Study: 31165710
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (DTG) - no intervention for 3 months
Study: 31260124
Drug: Tranilast 8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast 8% liposomal gel
Study: 28825957
Drug: Placebo (tranilast‐free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tranilast‐free liposomal gel)
Study: 26093951
Drug: Cisplatin-based chronotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin-based chronotherapy (administered at 18:00)
Study: 24282565
Drug: Mobile Teams
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Teams (MTs) providing counseling, condoms, screening and treatment for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) infections; presumptive metronidazole treatment.
Study: 21539680
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg daily
Study: 18997675
Drug: BUP (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP (300 mg) + NAL (50 mg)
Study: 12637255
Drug: Nandrolone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone (600 mg/wk) + Resistance Training (RT)
Study: 12637255
Drug: Nandrolone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone (600 mg/wk)
Study: 12637255
Drug: Oxandrolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (20 mg/day) + Placebo
Study: 10539752
Drug: 10 microgram
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microgram Se as L-selenomethionine
Study: 10539752
Drug: 20 microgram
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microgram Se as L-selenomethionine
Study: 10539752
Drug: 30 microgram
Normalized name: Levonorgestrel 30 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 microgram Se as L-selenomethionine
Study: 10539752
Drug: 40 microgram
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microgram Se as L-selenomethionine
Study: 28245835
Drug: Facilitation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitation of creams availability and continuous electronic monitoring of consumption with regular feedback on skin care performance.
Study: 17940809
Drug: Nadroparin (2,850/3,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (2,850/3,800 U daily subcutaneous)
Study: 12957685
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity in obese subjects
Study: 12957685
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity in non-obese subjects
Study: 8645511
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with prednisone for 6 weeks followed by alpha‐2a interferon (IFN) for 6 months (group A)
Study: 8645511
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of prednisone and IFN (group B)
Study: 1536049
Drug: Verapamil therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil therapy (120 mg thrice daily)
Study: 1536049
Drug: Verapamil therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil therapy (360 mg daily)
Study: 6678823
Drug: Domifen bromide
Normalized name: domiphen bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domifen bromide in combination with antibiotics
Study: 27488183
Drug: Yam bean
Normalized name: WILD YAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yam bean root juice (500 ml)
Study: 27488183
Drug: Guava fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guava fruit juice (500 ml)
Study: 7560220
Drug: Water (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (500 ml)
Study: 12909502
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin (5000 IU b.i.d.) and aspirin (100 mg daily)
Study: 11865427
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59
Study: 11865427
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine
Study: 11865427
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of both vaccines administered concomitantly
Study: 14726726
Drug: Methylphenidate (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (both doses)
Study: 25887302
Drug: Occupational medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational medicine intervention
Study: 24171490
Drug: Control (unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unfractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors)
Study: 15382303
Drug: CMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMT with surgery and chemotherapy
Study: 26817912
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after chemotherapy
Study: 9058513
Drug: Cyclic regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic regimen of interferon alpha‐2b (IFN‐alpha) at a dose of 10 MU/m2 body surface subcutaneously on 5 consecutive days every 4 weeks
Study: 27616628
Drug: BT (36-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT (36-session group Internet behavioral weight control treatment)
Study: 27616628
Drug: BT +
Normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT + MI (36-session group Internet behavioral weight control treatment + 6 individual MI chat sessions)
Study: 21334858
Drug: Solution Focussed
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution Focussed Group Therapy
Study: 18777606
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of static and dynamic magnetic fields (PEMF) applied 4 hours/day for 2 months
Study: 15636358
Drug: External Qi-therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: External Qi-therapy (EQT)
Study: 3481635
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) during sodium repletion (100 mmol/day)
Study: 3481635
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) during sodium depletion (20 mmol/day)
Study: 12393110
Drug: Propofol-ketamine (1-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-ketamine (1-1.5 mg/kg)
Study: 7843782
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril once daily in the morning for 5 days
Study: 2162692
Drug: Daily diary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily diary card during chemotherapy
Study: 412877
Drug: Intramuscular meptazinol
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meptazinol
Study: 10541446
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg, vitamin E, 30 mg, beta‐carotene, 6 mg) and minerals (selenium, 100 microg, and zinc, 20 mg)
Study: 10541446
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant vitamins and minerals
Study: 1684314
Drug: GHRH after
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH after saline infusion (Day 2)
Study: 1684314
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion followed by saline (Day 3)
Study: 1684314
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Day 1)
Study: 30002007
Drug: Best usual
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best usual primary care plus treatment with oseltamivir for 5 days
Study: 27936189
Drug: Peppy comments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppy comments from attending physicians (e.g., 'Hope you have a quiet day!')
Study: 20146365
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics (intravenous ceftazidime and tobramycin)
Study: 18953269
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Study: 12913771
Drug: Tormentil root
Normalized name: tormentil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tormentil root extract (3 drops per year of life, three times daily for up to 5 days)
Study: 12913771
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 drops per year of life, three times daily for up to 5 days)
Study: 1511566
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg three times per day)
Study: 6421015
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg NTG
Study: 30824339
Drug: GHB (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (20 mg/kg)
Study: 30824339
Drug: GHB (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (35 mg/kg)